Table 2. Characteristics of tuberculosis cases by isoniazid mono-resistance status, 24 EU/EEA countries, 2002–2014 (n = 194,948).
| Characteristics | Fully susceptible TB casesa |
INH mono-resistant TB cases |
||
|---|---|---|---|---|
| n | % | n | % | |
| Total | 187,370 | NA | 7,578 | NA |
| Sex | ||||
| Female | 64,640 | 34.5 | 2,566 | 33.8 |
| Male | 122,636 | 65.4 | 5,006 | 66.1 |
| Unknown | 94 | 0.1 | 6 | 0.1 |
| Age (years) | ||||
| Median (IQR) | 46 (32–60) | NA | 41 (30–54) | NA |
| Age group | ||||
| < 15 | 3,160 | 1.7 | 174 | 2.3 |
| 15–44 | 89,845 | 47.9 | 4,346 | 57.3 |
| 45–64 | 57,172 | 30.5 | 2,202 | 29.0 |
| > 64 | 37,127 | 19.8 | 855 | 11.3 |
| Unknown | 66 | 0.1 | 1 | 0.1 |
| Geographical origin | ||||
| Native | 131,344 | 70.1 | 4,639 | 61.2 |
| Foreign | 53,648 | 28.6 | 2,803 | 37.0 |
| Unknown | 2,378 | 1.3 | 136 | 1.8 |
| Type of TB | ||||
| Pulmonary | 160,231 | 85.5 | 6,341 | 83.7 |
| Extra-pulmonary | 26,813 | 14.3 | 1,219 | 16.1 |
| Unknown | 326 | 0.2 | 18 | 0.2 |
| Sputum smear microscopy | ||||
| Negative | 57,063 | 30.4 | 2,183 | 28.8 |
| Positive | 89,898 | 47.9 | 3,662 | 48.3 |
| Unknown | 40,409 | 21.7 | 1,733 | 22.9 |
| History of TB | ||||
| New TB case | 157,526 | 84.1 | 6,020 | 79.4 |
| Case with history of TB | 17,634 | 9.4 | 1,027 | 13.6 |
| Case with unknown TB history | 12,210 | 6.5 | 531 | 7.0 |
| HIV status | ||||
| Negative | 17,624 | 9.4 | 823 | 10.9 |
| Positive | 1,203 | 0.6 | 45 | 0.6 |
| Unknown | 168,543 | 90.0 | 6,710 | 88.5 |
| EU/EEA countries | ||||
| Low TB incidence | 74,742 | 40.0 | 2,582 | 34.1 |
| High TB incidenceb | 112,628 | 60.0 | 4,996 | 65.9 |
| Reporting years | ||||
| 2002–2005 | 49,532 | 26.4 | 2,089 | 27.6 |
| 2006–2009 | 61,478 | 32.8 | 2,403 | 31.8 |
| 2010–2014 | 76,360 | 40.8 | 3,086 | 40.6 |
| Number of TB cases by reporting countryc | ||||
| Austria | 5,716 | 96.6 | 203 | 3.4 |
| Bulgaria | 5,416 | 95.1 | 279 | 4.9 |
| Croatia | 953 | 98.0 | 19 | 2.0 |
| Cyprus | 224 | 91.8 | 20 | 8.2 |
| Czech Republic | 5,626 | 98.6 | 78 | 1.4 |
| Denmark | 807 | 95.7 | 36 | 4.3 |
| Estonia | 2,721 | 96.3 | 105 | 3.7 |
| Finland | 1,759 | 96.8 | 58 | 3.2 |
| Germany | 38,700 | 96.7 | 1,315 | 3.3 |
| Hungary | 4,663 | 95.6 | 216 | 4.4 |
| Iceland | 1 | 33.3 | 2 | 66.7 |
| Ireland | 1,725 | 95.7 | 78 | 4.3 |
| Latvia | 7,648 | 93.1 | 561 | 7.4 |
| Lithuania | 11,790 | 93.8 | 780 | 6.2 |
| Malta | 136 | 98.5 | 2 | 1.5 |
| Netherlands | 5,508 | 95.5 | 261 | 4.5 |
| Norway | 2,630 | 94.9 | 141 | 5.1 |
| Poland | 38,579 | 97.8 | 851 | 2.2 |
| Portugal | 15,764 | 97.1 | 477 | 2.9 |
| Romania | 3,032 | 92.9 | 233 | 7.1 |
| Slovenia | 2,346 | 98.9 | 26 | 1.1 |
| Slovakia | 3,697 | 97.7 | 86 | 2.3 |
| Sweden | 1,204 | 95.3 | 60 | 4.7 |
| UK | 26,725 | 94.1 | 1,691 | 5.6 |
| Final treatment outcome | ||||
| Treatment success | 144,961 | 77.4 | 5,611 | 74.0 |
| Death | 14,681 | 7.8 | 516 | 6.8 |
| Failed | 1,111 | 0.6 | 102 | 1.4 |
| Lost to follow-up | 10,259 | 5.5 | 567 | 7.5 |
| Not evaluated | 16,358 | 8.7 | 782 | 10.3 |
EU/EEA: European Union/European Economic Area; INH: isoniazid; IQR: interquartile range; NA: not applicable; TB: tuberculosis; TESSy: The European Surveillance System; UK: United Kingdom.
a TB cases susceptible to at least isoniazid, rifampicin, ethambutol and streptomycin.
b High-incidence countries were defined as those with 10 or more TB cases per 100,000 population in 2015 (Bulgaria, Croatia, Estonia, Latvia, Lithuania, Poland, Portugal, Romania and the UK).
c Seven countries (Belgium, France, Greece, Italy, Liechtenstein, Luxembourg and Spain) were excluded from this study, as they did not report treatment outcome and/or the required susceptibility data.
Data source: TESSy.